Skip to Content

FluLaval Quadrivalent Approval History

FDA Approved: Yes (First approved August 16, 2013)
Brand name: FluLaval Quadrivalent
Generic name: influenza virus vaccine
Company: GlaxoSmithKline
Treatment for: Influenza Prophylaxis

FluLaval Quadrivalent (influenza virus vaccine) is a vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.

Development History and FDA Approval Process for FluLaval Quadrivalent

DateArticle
Nov 18, 2016Approval GSK Receives FDA Approval for Expanded Indication for FluLaval Quadrivalent (Influenza Vaccine) for Infants 6 Months and Older
Aug 16, 2013Approval FDA Approves FluLaval Quadrivalent
Oct  5, 2006Approval FDA Approves FluLaval for Upcoming Influenza Season
Mar 23, 2006GlaxoSmithKline Submits Biologics License Application for FDA Approval of FluLaval

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide